Striverdi Respimat

  • Asthma/COPD

Striverdi Respimat Generic Name & Formulations

General Description

Olodaterol 2.5mcg; per actuation; inhalation spray; contains benzalkonium chloride.

Pharmacological Class

Long-acting beta-2 agonist (LABA).

How Supplied

Inhaler (w. cartridge)—4g (60 inh)

Generic Availability


Striverdi Respimat Indications


Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.

Limitations of Use

Not indicated to treat acute deteriorations of COPD or for treatment of asthma.

Striverdi Respimat Dosage and Administration


Take at same time each day. 2 inh once daily; max 2 inh/24hrs.


Not established.

Striverdi Respimat Contraindications


Use of LABA without inhaled corticosteroid (ICS) in asthma.

Striverdi Respimat Boxed Warnings

Not Applicable

Striverdi Respimat Warnings/Precautions


LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in acute deteriorating COPD. Not for relief of acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Discontinue if paradoxical bronchospasm or hypersensitivity reactions occur; use alternative therapy. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertrophic obstructive cardiomyopathy, hypertension). Convulsive disorders. Thyrotoxicosis. Prolongation of the QT interval. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Risk of hypokalemia or hyperglycemia. Severe hepatic impairment. Pregnancy. Labor & delivery. Nursing mothers.

Striverdi Respimat Pharmacokinetics

See Literature

Striverdi Respimat Interactions


Caution with concomitant other adrenergic drugs. Concomitant xanthine derivatives, steroids, K+-depleting diuretics may potentiate hypokalemia. Extreme caution with MAOIs, tricyclics, or drugs known to prolong QTc interval. Antagonized by β-blockers; if needed, consider cardioselective agents. Potentiated by strong CYP450 and P-gp inhibitors (eg, ketoconazole).

Striverdi Respimat Adverse Reactions

Adverse Reactions

Nasopharyngitis, URTI, bronchitis, UTI, cough, dizziness, rash, diarrhea, back pain, arthralgia.

Striverdi Respimat Clinical Trials

See Literature

Striverdi Respimat Note

Not Applicable

Striverdi Respimat Patient Counseling

See Literature